|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We analysed the distribution of the functionally important T91A SNP in the STK15 gene in a cohort of renal cell carcinoma (RCC) patients and compared it to the distribution in a control group without malignancies.
|
17143471 |
2007 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the present review, we will address the role of Aurora-A in cancer stem cells, as well as the outcomes of clinical trials assessing Aurora-A-specific small molecular inhibitors.
|
29544896 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study provides novel insights into an undisclosed role for the kinase AurkA in self-renewal and migration of BCICs affecting response to cancer therapies, metastatic spread and recurrence.
|
27341528 |
2016 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies.
|
21448591 |
2011 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aberrant expression and activity of Aurora kinase A is associated with numerous malignancies including colorectal cancer followed by poor prognosis.
|
28458622 |
2017 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In summary, this meta-analysis demonstrates that the STK15 F31I polymorphism may be a risk factor for cancer.
|
24349361 |
2013 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The Aurora-A/STK15 gene encodes a kinase that is frequently amplified in cancer.
|
17308110 |
2007 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The AURKA oncogene is associated with abnormal chromosome segregation and aneuploidy and predisposition to cancer.
|
17627006 |
2007 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A significant association was observed between malignancy as defined by Weiss score ≥3 and higher AURKA (2.0-fold, P = 0.01), AURKB (7.0-fold, P = 0.007), and BUBR1 (5.8-fold, P = 0.007) gene expression, and between unfavorable event (death or relapse) and higher expression of AURKA (6.0-fold, P = 0.034) and AURKB (17-fold, P = 0.013).
|
23788275 |
2013 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A significant effect of the STK15 rs2273535 polymorphism on cancer risk was found (AA vs. TT: OR=1.13, 95%CI=1.01-1.26, Pheterogeneity<0.001; AA vs.
|
24252226 |
2014 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MAP9 downregulation is associated with colorectal malignancy and could be used as a disease marker and a new drug target, while AURKA and PLK1 are upregulated.
|
24876664 |
2014 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These results confirm that the STK15 T+91A variant is a low penetrance cancer susceptibility allele affecting multiple cancer types, and provide genetic evidence from large-scale human population studies that genetic stability at the chromosome level is an important determinant of cancer susceptibility.
|
15802297 |
2005 |
|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aurora kinase A is a mitotic kinase commonly upregulated in cancer that causes regression of the primary cilium by promoting histone deacetylase-dependent tubulin depolymerization of the ciliary axoneme.
|
20864688 |
2010 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of AuA is implicated in poor prognosis of many types of cancer.
|
28915666 |
2017 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Higher BTAK expression was found in ovarian cancer cells compared to ovaries without cancer but with known BRCA1/2 mutation or strong family history (P<0.001), and expression levels of BTAK and p53 were directly correlated (r=0.306; P<0.001).
|
17673924 |
2007 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
STK15/Aurora-A is a serine/threonine kinase essential for chromosome segregation and cytokinesis, and is considered to be a cancer susceptibility gene in mice and humans.
|
15867347 |
2005 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correlation of expression levels of these markers in the oral cancer cohort of The Cancer Genome Atlas (n = 313) with treatment outcome identified 54 genes (p < 0.05 or fold change >2) associated with disease recurrence, 8 genes (NQO1, UBE2C, EDNRB, FKBP4, STAT3, HOXA1, RIT1, AURKA) being significant with high fold change.
|
30641296 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time PCR and immunohistochemistry analysis on matched cancer and corresponding normal tissues from surgically resected non-small cell lung cancers (NSCLC) have been performed aiming to explore the expression levels of AURKA gene.
|
21718475 |
2011 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As a molecular mechanism, we demonstrate that PTPRD interacts with aurora kinase A (AURKA), an oncogenic protein that is over-expressed in multiple forms of cancer, including neuroblastoma.
|
22305495 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aurora kinase A (AURKA/STK15/BTAK) encodes a serine/threonine kinase associated with chromosomal distribution and its up-regulation induces chromosomal instability, thereby leading to aneuploidy and cell transformation in several types of cancer.
|
16951231 |
2006 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of HPRT1, Jag2, AURKA, and PGK1 were elevated when compared to normal samples, and HPRT1 and PGK1 showed a stepwise elevation in expression that was significantly related to cancer grade.
|
30679932 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By using the AGS, FLO-1, and OE33 UGC cell lines, which have constitutive AURKA overexpression and variable tumor protein 53 (p53) status, significantly enhanced inhibition of cancer cell survival was observed with alisertib and docetaxel treatment in combination (P < .001), compared with single-agent treatments.
|
22972611 |
2013 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
|
31617432 |
2020 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
ALDH1A1 also reciprocates and prevents AURKA degradation, thereby triggering a positive feedback activation loop which drives highly aggressive phenotypes in cancer.
|
28193222 |
2017 |